all report title image
  • Published On : Jun 2022
  • Code : CMI5033
  • Industry : Pharmaceutical
  • Pages : 408
  • Formats :

Despite growth of biologic drugs, medicines based on small molecules remain important in the treatment of all types of diseases such as oncology disorders, infectious diseases, blood diseases, and cardiovascular diseases. Small molecule injectable drugs are often necessary for the treatment of patients. Advantages of small molecule injectable drugs over biologics are:

  • According to the Congressional Budget Office, in the year 2016, the small molecule drugs accounted for 84% of the pharmaceutical industry revenue. Moreover, Five of the top 10 drugs in terms of revenue, and nine out of the top 10 most-prescribed drugs, were based on small molecule APIs.
  • Intravenous infusion provides an immediate therapeutic effect by delivering medication directly into the bloodstream. For small molecule drugs, such rapid delivery is needed to treat patients, and is most often needed in hospitals either in an emergency room situation or when there are unexpected complications.
  • In some cases, patients are incapable of taking medications by mouth, and injection or infusion is the most effective route of administration. In others, the APIs may be degraded in the intestinal tract and therefore require parenteral delivery.
  • Furthermore, the injectable products are manufactured as per very high quality and sterility standards

Global Small Molecule Injectable Drugs Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to drive growth of the global small molecule injectable drugs market, owing to expansion of manufacturing facility during the COVID-19 pandemic. For instance, in 2021, Lonza, a pharmaceutical, biotechnology and nutrition products manufacturing company, was planning to expand its manufacturing facility by investing US$ 218.6 million to construct a new small molecule manufacturing facility at its site in Visp, Switzerland, the manufacturing facility will have six levels of manufacturing space. Initially, the company was built to manufacture antibody-drug conjugates (ADCs), including all required containment measures for manufacturing of these products.

Market players are involved in entering into agreements, in order to develop new medicines for the treatment of various diseases such as, oncology disorders, infectious diseases, blood diseases, and cardiovascular diseases, this is expected to increase growth of market, over the forecast period. For instance, in 2021, ViiV Healthcare made an upfront payment of US$ 40 million to Halozyme for the exclusive license to four HIV small and large molecule targets and is obligated to make potential future payments of up to US$ 175 million for development of commercial milestones per target. Halozyme will also be entitled to receive mid-single digit royalties on sales of commercialized medicines using the technology.

The global small molecule injectable drugs market is estimated to be valued at US$ 188.9 Bn in 2022 and is expected to exhibit a CAGR of 7.9% over the forecast period (2022-2030)  

Figure 1: Global Small Molecule Injectable Drugs Market Share, (%), Analysis, By Drug Class, 2022

Small Molecule Injectable Drugs  | Coherent Market Insights

Market players are indulged in making investments, in order to develop new small molecule injectable drugs. This is expected to drive growth of the global small molecule injectable drugs market over the forecast period.

Market players are involved in investments and this is expected to drive growth of the global small molecule injectable drugs market over the forecast period. For instance, in January 2021, Novartis AG, a global healthcare company, invested in Credence MedSystems, a drug delivery and specialty pharmaceutical company to develop the scale of its drug delivery systems. Credence will use the money to advance an injectable system designed to improve user experience and fit into existing biopharma processes.

Key players are engaged in receiving approvals for their small molecule injectable drugs from regulatory authorities and this is expected to drive growth of the global small molecule injectable drugs market over the forecast period.

Product approvals by market players is expected to drive growth of the global small molecule injectable drugs market over the forecast period. For instance, in August 2021, Aurobindo Pharma Ltd., a pharmaceutical company, announced that its subsidiary Eugia Pharma Specialties Limited., received approval for cyclophosphamide injection, from the U.S. Food and Drug Administrator (U.S. FDA) which is utilized in the treatment of various types of cancer such as lung cancer, Ewing's sarcoma (a type of bone cancer), and rhabdomyosarcoma (a type of cancer of the muscles).

CMI table icon

Small Molecule Injectable Drugs Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 188.9 Bn
Historical Data for: 2018 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 7.9% 2030 Value Projection: US$ 347.0 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Chemotherapy, Small Molecule Antibiotics, Skeletal Muscle Relaxants, Analgesics, Anticoagulants, Anticonvulsants, Antivirals, Others
  • By Indication: Oncology, Pain Management, Cardiovascular Diseases, Infectious Diseases, CNS Diseases, Others
  • By Mode of Delivery: IV Set, Infusion Pump, Intravenous Injection, Intramuscular Injection, Subcutaneous Injection
  • By End User: Hospitals, Ambulatory Clinics, Outpatient Facility, Infusion Therapy Center, Home Care, Others
Companies covered:

Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd. AstraZeneca Plc, Baxter International Inc., Fresenius Kabi AG, Cipla Limited., Mylan N.V., GlaxoSmithKline Plc., Johnson & Johnson, Sanofi S.A., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG (Genentech, Inc.), Amgen, Inc., Gilead Sciences, Inc., and Hikma Pharmaceuticals plc

Growth Drivers:
  • Increasing investments by market players for development of small molecule injectable drugs
  • Increasing product approvals by the regulatory authorities
  • Increasing prevalence of chronic diseases such as Alzheimer’s disease
Restraints & Challenges:
  • Increasing product recalls by regulatory authorities

Global Small Molecule Injectable Drugs Market – Restraints

Increasing number of product recalls is expected to hamper growth of the global small molecule injectable drugs market, over the forecast period. For instance, regulatory authorities such as U.S. FDA, are recalling some small molecule injectable drugs due to the presence of particulate matter identified as glass particles, which is expected to hinder growth of the global small molecule injectable drugs market over the forecast period. For instance, in October 2021, the U.S. Food and Drug Administration identified that Merck & Co. is recalling one lot of CUBICIN (daptomycin for injection) 500mg for intravenous usage. As treatment with CUBICIN is likely to be initiated at a hospital or other monitored healthcare setting, the recall is being conducted to the user level, including administering and hospital institutions. This recall affected around 22,000 vials.

Global Small Molecule Injectable Drugs Market – Regional Analysis

On the basis of region, the global small molecule injectable drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Among regions, North America small molecule injectable drugs market is expected to hold a dominant position during the forecast period, owing to increasing product approvals by regulatory authorities. For instance, in 2021, Baxter International Inc., a U.S.-based multinational healthcare company, announced that the U.S. Food and Drug Administration approved premix Norepinephrine Bitartrate in 5% Dextrose Injection. It is the only manufacturer-prepared ready-to-use formulation and is accessible in 8 mg/250 mL and 4 mg/250 mL strengths.

Moreover, in January 2021, ViiV Healthcare, a pharmaceutical company specializing in development of therapies for HIV infection, announced that Cabenuva (cabotegravir and rilpivirine, injectable formulation) was approved by the U.S. Food and Drug Administration (FDA) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine.

Furthermore, Europe is also estimated to witness significant growth in the global small molecule injectable drugs market, owing to increasing prevalence of chronic conditions such as cardiovascular diseases, Alzheimer’s disease, and hypertension. For instance, according to the data provided by the National Health Service, Scotland as of May 2021, it is estimated that Alzheimer's disease affected around 850,000 people in the U.K, and the number of patients suffering from Alzheimer’s disease is expected to rise to 1 million by 2025, and 2 million by 2050,

Figure 2: Global Small Molecule Injectable Drugs Market (US$ Bn), by Region, 2022

Small Molecule Injectable Drugs  | Coherent Market Insights

Global Small Molecule Injectable Drugs Market – Competitive Landscape

Major players operating in the global small molecule injectable drugs market include Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AstraZeneca Plc, Baxter International Inc., Fresenius Kabi AG, Cipla Limited., Mylan N.V., GlaxoSmithKline Plc., Johnson & Johnson, Sanofi S.A., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG (Genentech, Inc.), Amgen, Inc., Gilead Sciences, Inc., and Hikma Pharmaceuticals plc.  

The term ‘small molecule’ or low-molecular-weight organic compound means that the drug can be administered orally or that it can be injected through parenteral routes. Small-molecule injectable drugs are used in the treatment of oncology disorders, infectious diseases, blood diseases, and cardiovascular diseases.

Moreover, the small-molecule drugs are very easy to synthesize and can be produced in large quantities and also these drugs are very simple to manufacture, which leads to strong generic competition among market players. As small molecules typically work by mimicking biological substrates or allosterically targeting hydrophobic pockets of proteins, certain biological targets may not be druggable. Many bacterial and cancer cells have developed resistance to small-molecule drugs through mechanisms such as chemoenzymatic modifications, efflux pumps, drug target mutations, etc.

Market Dynamics

Market players are initiating production of injectable drugs in the new manufacturing facility, which is expected to drive growth of the global small molecule injectable drugs, over the forecast period. For instance, in August 2018, Pfizer Inc., a pharmaceutical and Biotechnology Corporation, announced injectable production at Portage in Kalamazoo, Michigan. The plant will enable Pfizer to produce injectable medicines for patients suffering from chronic diseases such as oncology, across the globe, as well as supporting the company’s supply capacity and production.

Key players are involved  in receiving approvals from regulatory authorities for new small molecule injectable drugs. This is expected to drive growth of the global small molecule injectable drugs market, over the forecast period. For instance in October 2020, Aurobindo Pharma Ltd., a pharmaceutical company, announced that they received approval from the U.S. Food and Drug Administration for its generic acetaminophen injection. It is indicated for the treatment of pain in pediatric patients and adults.

Moreover, in 2018, Aurobindo Pharma Ltd. announced that they received approval from U.S. Food and Drug Administration to manufacture and market Vecuronium Bromide Injection, 10mg and 20mg for the U.S. markets. This drug is utilized as a part of general anesthesia to give skeletal muscle relaxation during mechanical ventilation or surgery.

Key features of the study:

  • This report provides an in-depth analysis of the global small molecule injectable drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global small molecule injectable drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd. AstraZeneca Plc, Baxter International Inc., Fresenius Kabi AG, Cipla Limited., Mylan N.V., GlaxoSmithKline Plc., Johnson & Johnson, Sanofi S.A., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG (Genentech, Inc.), Amgen, Inc., Gilead Sciences, Inc., and Hikma Pharmaceuticals plc
  • Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global small molecule injectable drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global small molecule injectable drugs market

Detailed Segmentation:

  • Global Small Molecule Injectable Drugs Market, By Drug Class:
    • Chemotherapy
    • Small Molecule Antibiotics
    • Skeletal Muscle Relaxants
    • Analgesics
    • Anticoagulants
    • Anticonvulsants
    • Antivirals
    • Others
  • Global Small Molecule Injectable Drugs Market, By Indication:
    • Oncology
    • Pain Management
    • Cardiovascular Diseases
    • Infectious Diseases
    • CNS Diseases
    • Others
  • Global Small Molecule Injectable Drugs Market, By Mode of Delivery:
    • IV Set
    • Infusion Pump
    • Intravenous Injection
    • Intramuscular Injection
    • Subcutaneous Injection
  • Global Small Molecule Injectable Drugs Market, By End User:
    • Hospitals
    • Ambulatory Clinics
    • Outpatient Facility
    • Infusion Therapy Center
    • Home Care
    • Others
  • Global Small Molecule Injectable Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Novartis AG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Aurobindo Pharma Ltd.
    • AstraZeneca Plc
    • Baxter International Inc.
    • Fresenius Kabi AG
    • Cipla Limited.
    • Mylan N.V.
    • GlaxoSmithKline Plc.
    • Johnson & Johnson
    • Sanofi S.A.
    • Reddy’s Laboratories Ltd.
    • Hoffmann-La Roche AG (Genentech, Inc.)
    • Amgen, Inc.
    • Gilead Sciences, Inc.
    • Hikma Pharmaceuticals plc

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global small molecule injectable drugs market is expected to exhibit a CAGR of 7.9% during the forecast period (2022-2030).
The market is estimated to be valued at US$ 188.9 Bn in 2022.
Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd. AstraZeneca Plc, Baxter International Inc., Fresenius Kabi AG, Cipla Limited., Mylan N.V., GlaxoSmithKline Plc., Johnson & Johnson, Sanofi S.A., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG (Genentech, Inc.), Amgen, Inc., Gilead Sciences, Inc., and Hikma Pharmaceuticals plc are some of the prominent players operating in the market.
The market is expected to be valued at US$ 347.0 Bn in 2030.
North America is the prominent region in the market.
Small molecule antibiotics is the prominent segment among the drug class segment in the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo